Scrip's Five Must-Know Things - Oct. 19, 2026

Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended Oct. 16, 2026. This time—Tremfya rises from Stelara’s ashes; Pfizer uses mature brands as testbeds; Chinese science shines in Q3 deals; autoimmune win and setback for Argenx; and Japan looks to restore biopharma competitiveness.

Story links: insights.citeline.com/scrip/podcasts/scrips-fi…

This and all our other podcasts are available on the Scrip channel on Apple Podcasts (podcasts.apple.com/us/podcast/scrip-podcasts/i…), and Spotify Podcasts (open.spotify.com/show/54Ki1l5bTzuxvrUylwbvO9?s…) and on TuneIn (tunein.com/podcasts/Business--Economics-Podcas…).

Any comments? podcasts@norstella.com